In short
Clinical trials are currently underway to investigate the use of defatted powder from peanuts (Arachis hypogaea L.) as a potential treatment for peanut allergies. These studies aim to evaluate the safety and effectiveness of various methods to desensitize patients to peanut allergens, potentially improving quality of life for those with peanut allergies. The trials involve different approaches, including epicutaneous immunotherapy and oral food challenges, to assess how well patients can tolerate increasing amounts of peanut protein over time.
At a glance
- Study Types
- Phase 3 clinical trials
- Main Objectives
- Evaluate safety and efficacy of defatted peanut powder for peanut allergy treatment
- Treatment Methods
- Epicutaneous immunotherapy, oral food challenges
- Key Participants
- Children aged 4-7 with diagnosed peanut allergies
- Duration
- 12 months initial treatment, with potential extensions up to 3 years
- Primary Outcomes
- Increased tolerance to peanut protein, safety assessments
- Secondary Outcomes
- Quality of life improvements, long-term efficacy and safety
- Key Measurements
- Eliciting dose (ED), adverse events, immunological changes
What is Defatted Powder of Arachis Hypogaea L., Semen (Peanuts)?
Defatted powder of Arachis Hypogaea L., Semen (Peanuts) is a medical product derived from peanuts. It is being studied as a potential treatment for peanut allergies. This powder is created by removing most of the fat content from peanuts, leaving behind the protein components that are responsible for allergic reactions.
Medical Conditions Treated
The primary medical condition targeted by this treatment is peanut allergy. Peanut allergy is one of the most common food allergies and can cause severe, potentially life-threatening reactions in some individuals.
How It Works
This treatment works on the principle of immunotherapy. By exposing the patient to small, controlled amounts of peanut protein, the immune system can gradually become desensitized to the allergen. This process, known as desensitization, aims to reduce the severity of allergic reactions when accidentally exposed to peanuts.
Administration and Dosage
The defatted peanut powder is typically administered as granules for oral suspension. In some studies, it's also being tested as part of a patch applied to the skin, known as epicutaneous immunotherapy or EPIT. The dosage and administration method can vary depending on the specific study protocol and the patient's age and sensitivity to peanuts.
Clinical Trials and Research
Several clinical trials are currently underway to evaluate the effectiveness and safety of this treatment:
- A Phase 3 study called VITESSE is testing a product called DBV712 in children aged 4-7 years with peanut allergy.
- Another long-term study is evaluating the safety and efficacy of a drug called ligelizumab in patients who have completed previous Phase III studies in food allergy.
Efficacy and Benefits
The main goal of these treatments is to induce desensitization to peanuts. This means increasing the amount of peanut protein a person can tolerate without having an allergic reaction. For example, one study aims to have patients tolerate at least 300-600 mg of peanut protein after 12 months of treatment. Another study is looking at whether patients can tolerate 600 mg or more of peanut protein during an open-label oral food challenge.
Safety and Side Effects
As with any medical treatment, safety is a primary concern. The clinical trials are closely monitoring for adverse events, including:
- Local reactions at the site of application (for patch treatments)
- Systemic allergic reactions
- Any events requiring the use of epinephrine
- Changes in asthma control
It's important to note that these treatments are still being studied, and the full range of potential side effects may not yet be known.
Patient Eligibility
Not all patients with peanut allergies may be eligible for these treatments. Eligibility criteria often include:
- Age (often between 4-7 years for pediatric studies)
- Confirmed peanut allergy diagnosis
- No history of severe anaphylaxis to peanuts
- Absence of certain medical conditions (e.g., uncontrolled asthma, certain skin conditions)
- Willingness to follow a strict peanut-free diet during the study
It's crucial to consult with an allergist or immunologist to determine if you or your child might be eligible for such treatments.
Impact on Quality of Life
One of the secondary objectives of these studies is to assess the impact of treatment on patients' health-related quality of life (HRQoL). Living with a peanut allergy can significantly affect a person's daily life, causing anxiety and limiting food choices. If successful, these treatments could potentially improve patients' quality of life by reducing the fear and risks associated with accidental peanut exposure.